Undisclosed Oral APJ Agonist / BioAge Labs - LARVOL DELTA

APJ agonist program advancement (GlobeNewswire) - "BioAge continues to advance its oral and injectable APJ agonist development strategy, including a novel APJ agonist antibody that is the subject of an option agreement with JiKang Therapeutics. The Company intends to file its first IND for an APJ program by year-end 2026."

IND • Obesity

First Quarter 2026 Business Highlights (GlobeNewswire) - "The Company plans to initiate a Phase 1b/2a proof-of-concept trial in mid-2026, with results anticipated in mid-2027...APJ agonist program advancement...The Company intends to file its first IND for an APJ program by year-end 2026."

IND • New P1/2 trial • P1/2 data • Diabetic Macular Edema • Obesity

APJ agonist program advancement (The Manila Times) - "BioAge intends to file the first IND for an APJ program by 2026 year end."

IND • Obesity

APJ agonist program advancement (The Manila Times) - "The Company continued to advance its oral and parenteral APJ agonist development strategy....Both programs are targeting IND submissions in 2026."

IND • Obesity